- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01950780
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In the disease, the immune system mistakenly destroys the hair follicle, causing hair to fall out. Despite many people having this disease, research into its cause and into new, better ways to treat AA has lagged far behind other similar diseases of the immune system. Currently, there are no Federal Drug Administration approved drugs for AA.
Ruxolitinib (made by Incyte) is an intervention known to effectively treat a disease of the bone marrow, known as myelofibrosis. It is also being studied in the treatment of rheumatoid arthritis, another "autoimmune" disease, by fighting inflammation. There are some genetic and chemical similarities between those with myelofibrosis, active rheumatoid arthritis and AA, suggesting that treatment with ruxolitinib may be effective in AA. In mice specially designed for testing drugs for the treatment of human alopecia areata, this medication worked to prevent the disease AA from starting in mice that would have otherwise developed the disease. To test Ruxolitinib, we are going to treat 12 patients with moderate to severe AA for a minimum of 3 months up to 6 months. This is an "open-label" study, meaning that there will not be a placebo group; all patients enrolled in the study will receive the active medication. The effectiveness of the medication will be measured by changes in hair re-growth as determined by physical exam and photography, as well as by patient and physician scoring. Patients will be followed for another 3 months off of the drug to see if the effects of treatment last and if there is delayed response. The safety of the medication, ruxolitinib, in patients with alopecia areata will also be evaluated.
Blood work will be collected before medication is started, during the treatment period, and after ruxolitinib is stopped, in order to monitor for adverse effects of the medication. Small scalp biopsies and peripheral blood will be taken at the beginning of the study before treatment and also after 12 and possibly 24 weeks. Optional biopsies may also be taken at additional time points based on clinical considerations. The chemical analysis of these skin samples and blood will help us to understand how the disease happens, how the treatment works, and may even guide us to better treatments in the future.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Columbia University Medical Center, Department of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between 18 to 75 years of age.
- Patients with a diagnosis of patch type alopecia areata.
- Patients will have >30% and <95% total scalp hair loss at baseline as measured using the SALT score. Two patients with current episodes of alopecia totalis/universalis may be included in this study.
- Duration of hair loss greater than 3 months.
- No evidence of regrowth present at baseline.
- Patients may be naïve to treatment or unresponsive to intralesional (IL) steroids or other treatments for alopecia areata.
Exclusion Criteria:
- Patients with a history of or active skin disease on the scalp such as psoriasis or seborrheic dermatitis.
- Patients in whom the diagnosis of alopecia areata is in question.
- Patients with active medical conditions or malignancies (except adequately treated basal or squamous cell carcinoma) that in the opinion of the investigator would increase the risks associated with study participation, including patients with a history of recurrent infections.
- Women of childbearing potential who are unable or unwilling to use two forms of birth control for the study duration.
- Women who are pregnant or nursing.
- Patients known to be HIV or hepatitis B or C positive.
- Patients with history or evidence of hematopoietic abnormality.
- Patients with <200K platelet count at baseline.
- Patients with history or evidence of renal or hepatic impairment.
- Patients with history of immunosuppression or history of recurrent serious infections.
- Patients unwilling or unable to discontinue treatments known to affect hair regrowth in AA.
- Patients taking any medication considered a strong CYP3A4 inhibitor who is unable or unwilling to stop this medication for the duration of the study.
- Patients receiving treatment deemed to affect alopecia areata within 2 weeks to one month of baseline visit depending on the specific treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ruxolitinib
A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks.
Dosing may be decreased or held if needed due to adverse effects.
|
A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks.
Dosing may be decreased or held if needed due to adverse effects.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in SALT Score
Time Frame: Baseline, 3 months and 6 months
|
Severity of Alopecia Tool Score (SALT) calculation is based on a scoring system.
The scalp is divided into the following 4 areas: 1) Vertex: 40% (0.4) of scalp surface area, 2) Right profile of scalp: 18% (0.18) of scalp surface area, 3) Left profile of scalp: 18% (0.18) of scalp surface area, and 4) Posterior aspect of scalp: 24% (0.24) of scalp surface area.
The percentage of hair loss in any of these areas is the percentage hair loss multiplied by percent surface area of the scalp in that area.
The SALT score is the sum of percentage of hair loss in all the above-mentioned areas, so a lower number indicates a better outcome.
The reported SALT score range is from a minimum of 0 (no hair loss) to a maximum of 100 (100% hair loss).
|
Baseline, 3 months and 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Regrowth
Time Frame: Up to 6 months
|
Mean percentage of regrowth was calculated at the end of treatment for all subjects.
|
Up to 6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julian Mackay-Wiggan, MD, MS, Columbia University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAL7102
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia Areata
-
Eli Lilly and CompanyRecruitingSkin Diseases | Pathological Conditions, Anatomical | Alopecia | Hypotrichosis | Hair Diseases | Areata AlopeciaUnited States, Taiwan, Japan, Spain, Korea, Republic of, Germany, France, Mexico, Canada, Poland, Australia, Hungary, Argentina
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdActive, not recruitingAlopecia Areata(AA)China
-
University Hospital, RouenCompletedALOPECIA AREATAFrance
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Inmagene LLCRecruitingAlopecia Areata (AA)United States, Canada
-
Services Institute of Medical Sciences, PakistanCompletedExtensive Alopecia AreataPakistan
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
EquilliumWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Lindsey BordoneWithdrawnAlopecia Areata | Alopecia Totalis | Alopecia Universalis
-
Aclaris Therapeutics, Inc.Completed
Clinical Trials on Ruxolitinib
-
First Affiliated Hospital of Zhejiang UniversityXiangya Hospital of Central South University; Second Affiliated Hospital, School... and other collaboratorsRecruitingHematologic Malignancy | Bronchiolitis Obliterans SyndromeChina
-
Novartis PharmaceuticalsTerminatedMyelofibrosis With High Molecular Risk MutationsBelgium, Spain, United Kingdom, Hungary, Italy, Japan, Taiwan, Germany, Canada, Singapore, Austria, Australia, France, Israel, Sweden, Switzerland, Hong Kong, Greece, Turkey, Brazil, Russian Federation, Denmark, Portugal, Norway, Poland
-
Julie NangiaIncyte Corporation; Translational Breast Cancer Research ConsortiumRecruitingDuctal Carcinoma In Situ | Atypical Ductal Hyperplasia | Atypical Lobular Hyperplasia | Lobular Carcinoma In SituUnited States
-
Incyte CorporationActive, not recruiting
-
Beijing Friendship HospitalUnknownHemophagocytic LymphohistiocytosisChina
-
Children's Hospital Medical Center, CincinnatiRecruitingBronchiolitis Obliterans (BO) | Hematopoietic Stem Cell Transplant (HSCT)United States
-
University of JenaCompleted
-
University of Michigan Rogel Cancer CenterCompletedHemophagocytic Syndrome (HPS)United States
-
Margherita MaffioliUnknown
-
University of PittsburghWithdrawnHead and Neck Squamous Cell Carcinoma